Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective trial to evaluate safety and efficacy of estrogen therapy in multiple formulations in menopausal women

X
Trial Profile

A prospective trial to evaluate safety and efficacy of estrogen therapy in multiple formulations in menopausal women

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 26 May 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Estrogen (Primary)
  • Indications Menopausal syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 May 2016 New trial record
    • 10 Feb 2016 According to a Viramal media release, the company has planned 6 studies in women's health including phase I/II, expected to initiate between Q2 2016 and 2017, subject to funding. The company is in the process of finalizing INDs for the drugs, including products to treat infertility in women with endometriosis and limit side effects of existing therapies, and provide estrogen therapy in multiple formulations for menopausal women.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top